Novamex USA Ltd.

Novamex USA Ltd.

September 12, 2005 09:41 ET

Novamex USA Ltd. Signs Corporate Finance Agreement with MagnaCarta Capital Markets

VILLE SAINT LAURENT, QUEBEC--(CCNMatthews - Sept. 12, 2005) - Novamex USA Ltd. (PINK SHEETS:NOVM) is pleased to announce that it has signed an agreement with MagnaCarta Capital Markets of Montreal, under which MagnaCarta will assist Novamex in raising funds, establishing a professional investor relations program and advising Novamex on corporate acquisitions. The agreement is valid for a period of 3 years.


NOVAMEX is a development stage biotechnology company, incorporated in the state of Oregon, working in the field of rapid diagnostic tests using immunodetection, specifically for agri-food and veterinary applications. The tests developed by NOVAMEX are based on the use of monoclonal antibodies specifically directed against the surface structures unique to each molecule, bacteria or virus. These tests are very specific and very sensitive. Reading and interpreting of the result is done visually by means of a solid-phase colorimetric reaction. The Novamex technology has also been applied to a test it has developed for Bovine Spongiform Encephalopathy (BSE) commonly referred to as "Mad Cow Disease."


MagnaCarta Capital Markets was founded by a group of corporate finance
professionals coming from Investment-Dealers, Banks and Trading Desks of
various organizations. MagnaCarta Capital Markets is an independent Investment
Banking firm that operates under the auspices of the Jitney Group, a broker-
dealer that was created by floor traders of the Montreal Stock Exchange who
became suddenly orphan when the exchange floor closed in 2001. The firm is an
investment banking boutique that specialise in M&A, Mid-Cap and Small Cap
companies and inter-brokers and institutional services like transition
management, commission recovery, block trades and alternative financing

Novamex USA Ltd. is listed on the Pink Sheets, under the symbol NOVM and plans to apply for listing on the OTCBB once it has brought its filings current with the SEC.


This PRESS RELEASE contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which act contains a safe harbor for forward looking statements. Statements made in connection with initial public offerings, however, are not protected by the safe harbor of the Private Securities Litigation Reform Act of 1995. Nonetheless, the Company believes that investors would be benefited by the cautionary language included in this paragraph. For this purpose any statements contained in this PRESS RELEASE that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," anticipate," "estimate," or "continue" or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within the Company's control. These factors include but are not limited to economic conditions generally and in the industries in which the Company may participate; competition within the Company's chosen industry, including competition from much larger competitors; technological advances, regulatory and legal considerations, failure by the Company to successfully obtain proper financing, and failure to develop business relationships. Further, the Company assumes no obligation to update or otherwise publicly revise the forward-looking information disclosed herein to reflect circumstances existing after the date hereof.

Contact Information